Ocugen reports Q2 2023 financial results; pipeline update highlights NR2E3 gene therapy

Ocugen, Inc.

2023-Q2 EPS reported -$0.17 revenue$928,000

Reported financial results for quarter ended June 30, 2023; no specific figures available in filing text.
Business update discussed gene therapy programs including NR2E3 modifier gene and NHR platform.
Presentation materials furnished as Exhibit 99.1 describe 'molecular reset' approach for retinal diseases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Ocugen, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Ocugen, Inc. (the "Company") held a conference call and webcast earlier today to discuss its financial results for the quarter ended June 30, 2023, along with a general business update.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-030175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.